To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

Completed · Phase 2

Conditions studied: Superficial Basal Cell Carcinoma

In brief

The purpose of this study is to determine maximum tolerated dose level (MTD) of PEP005 Topical Gel for the treatment of superficial basal cell carcinoma on the trunk

Key facts

Study ID

NCT00432185

Run by

Peplin

People needed

117

Starts

2007-02-01

Expected to finish

2010-03-01

Last updated by the study team

2016-02-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Alta Dermatology — Mesa, Arizona, United States
• Dermatology Specialists Inc. — Oceanside, California, United States
• Skin Surgery Medical Group Inc. — San Diego, California, United States
• Colorado Medical Research Center — Denver, Colorado, United States
• Advanced Dermatology and Cosmetic Surgery — Clermont, Florida, United States
• Park Avenue Dermatology — Orange Park, Florida, United States
• Minnesota Clinical Studies Center — Fridley, Minnesota, United States
• Dermatology Associates of Rochester — Rochester, New York, United States
• Rivergate Dermatology and Skin Care Center — Goodlettsville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.